Usage of cookies

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our Privacy policy.

Skip to content

Marketed Products

Our reward is real progress. The satisfaction of knowing that what we are doing really helps.

We have a marketed range of drug-free treatments for osteoarthritis which reduce pain and stiffness, improve joint movement and offer welcome relief from a condition that affects 20% of adults worldwide.


Our products

FlexiSEQ is a topical drug-free gel for lubricating the cartilage in joints to relieve pain and stiffness, and improve joint function associated with all stages of osteoarthritis.

FlexiSEQ Max Strength: Our maximum strength formulation

FlexiSEQ Max Strength: Our maximum strength formulation

If you have diagnosed osteoarthritis, nothing but the best will do. That’s why FlexiSEQ Max Strength is loaded with our max strength formulation, tested in clinical trials with the most demanding patients. FlexiSEQ Max Strength provides proven, drug free relief from the pain and stiffness of osteoarthritis. A drug-free, sustainable solution to effectively relieve the pain and stiffness of osteoarthritic joints to keep you moving.

FlexiSEQ Joint Wear and Tear: Our lighter strength formulation

FlexiSEQ Joint Wear and Tear: Our lighter strength formulation

FlexiSEQ Joint Wear and Tear contains a lighter formulation of our original, drug free, joint lubricating technology, for active joints affected by everyday wear and tear. Whether you are cycling to work, walking the hills, jogging with the dog or taking a weekend Zumba class, FlexiSEQ Joint Wear and Tear provides trusted relief from the pain and stiffness of joint wear and tear to keep you moving.

About FlexiSEQ

Research on joint disorders

Patients with joint disorders such as osteoarthritis have been found to have reduced levels of synovial lubricants that play a key role in protecting articulating cartilage. Research has shown that liposomal aggregates that are highly compressible, soft and are highly hydrated make effective biolubricants. A study with topically applied, fluorescently labelled Sequessome vesicles showed that the Sequessomes travel to the synovium, where they arrive intact and distribute themselves on the surface of the cartilage, forming a protective, lubricating layer.

FlexiSEQ efficacy

By exploiting this lubricating mechanism, FlexiSEQ demonstrated clear efficacy in a large scale, Phase III, 12-week trial, compared to the oral selective, COX2 painkiller, celecoxib. These data are shown below:

WOMAC pain sub scale:
mean difference from baseline

Proportion of patients reporting
Gastrointestinal Events

FlexiSEQ safety profile

The excellent safety profile has been further demonstrated by the total lack of any systemic side effects being related to the product in over 90 million doses sold worldwide.

What healthcare professionals are saying about FlexiSEQ

The advantages of FlexiSEQ have been recognised by key persons within the arthritis medical community and leading physio-therapy/sports rehabilitation:

“There are fewer and fewer safe, available, pain-relieving options for people with osteoarthritis. If this product can relieve their long-term pain without side-effects, then that’s good news for the millions of people who suffer with this debilitating condition.” Arthritis Research UK.

“This is a fantastic product and one the medical team are proud and happy to have associated with the Club” – Joe Collins, former Head of Saracens Medical Team and now High Performance Manager of Buffalo Sabres (NHL) and Director of Performance Science of Buffalo Bills (NFL).

FlexiSEQ trial data have been published in a number of journals: Current Medical Research and Opinion, Rheumatology, Journal of Rheumatology, and Journal of Pain Research.